Baigent C, et al. - In this randomized, open-label trial involving 537 participants, researchers estimated the relative and absolute effects of antiplatelet therapy on recurrent intracerebral hemorrhage and if this risk might exceed any reduction of occlusive vascular events. According to results of the REstart or STop Antithrombotics Randomised Trial (RESTART), only a very modest increase in the risk of recurring intracerebral hemorrhage was seen with antiplatelet therapy, which appeared to be too small to exceed the established benefits of antiplatelet therapy for the secondary prevention of major vascular events. Intracerebral hemorrhage recurrence may have been reduced by antiplatelet therapy. These findings provide reassurance in clinical practice regarding the use of antiplatelet therapy for analogous patients.